NextenBio Rosbivo Signs MTA for Diabetes Treatment with Global Pharma Eli Lilly
[Asia Economy Reporter Jang Hyowon] Nexten Bio announced on the 22nd that its subsidiary RosVivo Therapeutics (hereinafter RosVivo) has signed a Material Transfer Agreement (MTA) with the global pharmaceutical company Eli Lilly for the commercial development of the new drug candidate for diabetes treatment, ‘RSVI-301’, targeting diabetes and obesity.
This MTA is one of a series of steps toward license-out, and is a contract to transfer the material developed by the company to the counterpart company in order to verify the efficacy and research results of the material through experiments for technology transfer and research and development progress.
Through several prior animal comparative experiments, RosVivo confirmed the overwhelming superiority and permanence of the ‘candidate substance RSVI-301’ compared to GLP1 receptor agonists, which are called game changers for diabetes and obesity treatments. It is known that Eli Lilly reviewed and acknowledged the animal experimental data and plans to reconfirm the excellence of RSVI-301 directly through this MTA.
RosVivo’s ‘RSVI-301’ is the world’s first new drug candidate that applies miRNA technology to restore the function of beta cells that secrete insulin, the cause of diabetes, and simultaneously reduce insulin resistance, fundamentally treating diabetes. Currently, diabetes drugs only temporarily lower blood sugar levels, so diabetes is not fundamentally cured.
Additionally, RSVI-301 showed excellent therapeutic effects on obesity, fatty liver, and digestive gastrointestinal disorders in animal tests, making it an ideal next-generation diabetes treatment drug candidate with fewer side effects.
Hot Picks Today
"You Might Regret Not Buying Now"... Overseas Retail Investors Stirred by News of Record-Breaking Monster Stocks' IPOs
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- Mistaken for the Flu, Left Untreated... Death Toll Surges as WHO Declares Emergency (Comprehensive)
- Pompidou Center Hanwha Unveils Picasso Works, Opens to Public on June 4
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
A RosVivo official said, “Progressing from CDA to this MTA with the global diabetes treatment company ‘Eli Lilly’ proves the potential of the new drug candidate substance and gives us confidence in license-out,” adding, “Besides ‘Eli Lilly’, several global pharmaceutical companies continue to show strong interest in RosVivo’s candidate substance.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
